. 2020 Mar 27;182(6):583–594. doi: 10.1530/EJE-19-0762
This work is licensed under a Table 7.
Mean FPG and HbA1c values at the end of the extension study and change in actual values in FPG and HbA1c from baseline to end of the extension.
| Baseline diabetic status | Long-acting pasireotide 40 mg | Long-acting pasireotide 60 mg | Crossover group | |||
|---|---|---|---|---|---|---|
| Actual | Change from baseline | Actual | Change from baseline | Actual | Change from baseline | |
| FPG, mg/dL | ||||||
| Diabetic, n
Mean (s.d.) Median (range) |
24 136 (32) 137 (85–189) |
24 22 (32) 22 (–43to79) |
21 168 (80) 148 (99–364) |
21 52 (84) 20 (–40to238) |
26 152 (50) 135 (97–303) |
26 37 (43) 25 (–9to168) |
| Pre-diabetic, n Mean (s.d.) Median (range) |
9 117 (30) 115 (74–159) |
9 17 (34) 12 (–36to74) |
11 133 (38) 121 (96–227) |
11 28 (38) 20 (–2to131) |
10 116 (18) 112 (92–142) |
10 15 (16) 8 (–4to44) |
| Normal glucose tolerance, n Mean (s.d.) Median (range) |
2 125 (1) 125 (124–126) |
2 28 (4) 28 (25–30) |
2 158 (6) 158 (153–162) |
2 71 (5) 71 (67–74) |
1 96 (–) 96 (–) |
1 10 (–) 10 (–) |
| HbA1c, % | ||||||
| Diabetic, n
Mean (s.d.) Median (range) Pre-diabetic, n Mean (s.d.) Median (range) Normal glucose tolerance, n Mean Median (range) |
23 7.0 (1.1) 6.8 (5.6–9.5) 9 6.1 (0.6) 6.1 (5.1–7.0) 2 5.9 (0.1) 5.8 (5.8–5.9) |
23 0.8 (0.9) 1.0 (–1.5to2.3) 9 0.5 (0.5) 0.4 (–0.1to1.3) 2 0.3 (0.1) 0.3 (0.2–0.3) |
20 7.9 (1.9) 7.2 (5.8–12.2) 11 6.7 (2.1) 6.0 (5.6–13.0) 3 6.8 (1.0) 6.5 (6.0–7.9) |
20 1.8 (1.9) 1.0 (–0.3to6.1) 11 1.0 (2.1) 0.3 (–0.2to7.1) 3 1.4 (0.9) 1.2 (0.6–2.4) |
29 7.3 (1.1) 7.4 (5.3–10.1) 10 6.1 (0.5) 6.2 (5.4–6.9) 1 6.2 (–) 6.2 (–) |
29 1.3 (1.0) 1.3 (–0.1to4.0) 10 0.4 (0.4) 0.4 (–0.3to0.9) 1 0.6 (–) 0.6 (–) |